drugset / Trial / NCT01158105
Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see if bortezomib (Velcade) is effective in the treatment of refractory cGVHD.
Timeline
- Start
- 2010-06
- Primary completion
- 2013-05
- Completion
- 2017-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.6 mg/m2 | Intravenous |